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Summary
Since the first cases of COVID-19 were reported from China the disease became pandemic within a few months. 
The viral genome was sequenced soon after the outbreak of COVID-19 which enabled development of diagnos-
tic tests and therapeutic options. As the knowledge of SARS-CoV-2 virology increased, many potential drugs 
appeared. At this moment (January 12th 2021), 4426 studies of COVID-19 are registered, and more than 2680 
studies are investigating therapeutic options. This is a short narrative review of currently available evidence on 
pharmacological treatment of COVID-19.
Sažetak
U roku nekoliko mjeseci od pojave prvih slučajeva COVID-19 u Kini, bolest je poprimila pandemijske razmjere. 
Virusni genom je sekvencioniran ubrzo nakon pojave COVID-19 što je omogućilo razvoj dijagnostičkih testova 
i terapije. Kako su pristizala saznanja o samom virusu SARS-CoV-2, pojavljivali su se razni potencijalni lijekovi. 
U ovom trenutku (12. siječnja 2021.) registrirano je 4426 studija o COVID-19, a više od 2680 studija se bavi 















 The pandemic novel coronavirus disease 2019 
(COVID-19) rapidly spread worldwide since the be-
ginning in Wuhan, China in the end of December 
2019[1]. Soon after the outbreak in Wuhan has been 
recognized, a causative agent was discovered. The vi-
rus was firstly named a novel coronavirus, 2019-nCoV, 
but it was soon renamed to SARS-CoV-2[2]. It is a sin-
gle-stranded RNA virus of approximately 27–32 kb 
and the seventh member of the family Coronaviridae 
that causes illness in humans[2,3]. The viral genome 
was sequenced soon after the outbreak of COVID-19 
which enabled development of diagnostic tests and 
therapeutic targets[2]. Until January 3rd, a total of 83 
326 479 COVID-19 cases and 1 831 703 deaths were 
reported globally[4]. As a result of pandemic's pro-
found impact on healthcare systems worldwide, many 
clinical trials assessing the efficacy of different thera-
peutic options emerged. Until April 24th, over 500 clin-
ical trials on COVID-19 treatment were registered[5] 
and at this moment (January 12th 2021) 2680 studies 
of treatment are registered on Clinicaltrials.gov. There 
is no evidence of benefits of prophylactic therapy and 
it will not be discussed here[6]. This review will give 
an overview of current knowledge of pharmacologic 
treatment of COVID-19.
Antiviral drugs
Remdesivir – possible benefit in some patients
 Remdesivir (GS-5734) is a novel nucleotide ana-
logue prodrug in a parenteral form. Currently, it is the 
only antiviral drug against SARS-CoV-2 confirmed to 
be effective in clinical trials. It undergoes metabolic 
conversion in cells to active metabolite which inhibits 
viral RNA-dependent RNA polymerase[7]. Remdesivir 
was discovered during the screening process for drugs 
with activity against Coronaviridae and Flaviviridae 
and showed activity against SARS-CoV-2 in vitro[6-8]. 
The pharmacokinetics of remdesivir was evaluated in 
phase one clinical trials on Ebola[7]. Serum and intra-
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a Janus kinase inhibitor (baricitinib) was compared to 
remdesivir alone. Faster recovery was observed in the 
remdesivir plus baricitinib group of patients (Table 1)
[15]. Serious adverse events to remdesivir were not fre-
quently observed in randomized trials. In the NIAID 
ACTT-1 study adverse reactions leading to treatment 
discontinuation were recorded in 2% of patients receiv-
ing remdesivir and in 3% receiving placebo[12]. In the 
study by Goldman et al.[13] the most common adverse 
events were nausea (9%), worsening respiratory failure 
(8%), elevated ALT (7%), and constipation (7%).
Favipravir- more data needed
 Favipravir (T705) is an oral prodrug of a purine 
nucleotide which inhibits the RNA-dependent RNA 
polymerase and induces lethal RNA transversion mu-
tations[16]. Safety and efficacy of favipiravir has been 
confirmed in influenza and it is currently available 
for the treatment of influenza in Japan[6, 17]. Previous 
clinical trials conducted during the Ebola outbreak 
suggested that favipiravir is active in Ebola patients 
with high viral load[16]. Studies on the healthy subjects 
showed a short half‐life time of favipravir of 2–5.5 
hours[6, 17]. Dosing varies and depends on the type of 
infectious disease; higher doses should be considered 
for the treatment of COVID-19[6]. Optimal dose and 
duration of treatment is still not known and current-
ly used dosage schemes are: 1600 mg every 12 hours 
first day (q12h), followed by 600 mg q12h for a to-
tal duration of 7 to 14 days[18]. Another clinical trial 
(NCT04303299) is using a dose of 2400 mg every 8 
hours for 2 doses, followed by a dose of 1200 mg every 
8 hours on day 1, followed by maintenance dose of 
1200 mg twice daily. No differences in clinical out-
comes were found between favipiravir plus inhaled 
interferon beta-1b vs. hydroxychloroquine in 89 adults 
hospitalized due to moderate or severe COVID-19 
pneumonia[19]. A small open label clinical trial com-
pared the effects of favipiravir plus interferon (IFN)-α 
by aerosol inhalation (N=35) with lopinavir/ritonavir 
plus IFN-α by aerosol inhalation (N=45)[18]. In the fa-
vipravir arm, a shorter viral clearance (median 4 days 
vs 9 days, p<0.001), improvement in chest imaging 
(91.43% vs 62.22%, p=0.004) and fewer adverse reac-
tions were observed[18]. In a prospective, randomized, 
multicentre study favipiravir (n = 120) was compared 
to arbidol (n = 120) for treatment of COVID-19 pa-
tients[20]. There were no differences in clinical recovery 
rate at day 7, but favipiravir had shorter time to relief 
for pyrexia (difference: 1.70 days, p<0.0001) and cough 
(difference: 1.75 days, p<0.0001)[20]. Randomized pla-
cebo-controlled trials evaluating favipravir as a treat-
ment of COVID-19 are underway (NCT04464408, 
spectively, intravenous doses between 3 mg and 225 mg 
were well tolerated and it demonstrated linear pharma-
cokinetics within the dose range[6]. A renal adjustment 
dose has not been evaluated, however, remdesivir is not 
recommended for patients with an estimated glomeru-
lar filtration rate < 30 mL/min. After multiple admin-
istrations of remdesivir, aspartate aminotransferase 
(AST) and ALT elevation have been observed[6]. There 
are no dosage adjustments for baseline hepatic impair-
ment, however, if hepatotoxicity (alanine aminotrans-
ferase [ALT] >10 times the upper normal limit or ALT 
elevation and signs or symptoms of liver inflammation) 
develops during treatment remdesivir should be dis-
continued. Remdesivir is not considered genotoxic[7]. 
Currently remdesivir is used as a single 200 mg dose, 
followed by 100 mg daily. The total duration of therapy 
is 5 or 10 days, depending on the response and severity 
of disease. If there is no clinical improvement or pro-
gression of disease a 10-day course is recommended[9,
10]. A randomized, double-blind, placebo-controlled, 
multicentre trial in China, which involved 237 adults 
with confirmed SARS-CoV-2 infection and radiolog-
ically confirmed pneumonia showed no difference in 
time to clinical improvement among patients who re-
ceived remdesivir and patients who received placebo 
(hazard ratio (HR) 1.23 [95% CI 0.87–1.75]) and mor-
tality at day 28 was similar (14% vs 13%, respectively) 
(Table 1)[11]. However, patients (with symptom dura-
tion of 10 days or less) who received remdesivir had a 
faster time to clinical improvement (HR 1.52 [95% CI 
0.95–2.43]), although not statistically significant[11]. In 
this trial concomitant use of lopinavir–ritonavir, inter-
ferons, and corticosteroids were not permitted[11]. The 
final results from randomized, double-blind, place-
bo-controlled trial NIAID ACTT-1 on 1062 Covid-19 
patients with evidence of lower respiratory tract in-
volvement showed that 541 patients treated with rem-
desivir intravenously (200 mg on day 1, followed by 
100 mg daily for 9 days) had a shorter time to recovery 
compared to placebo group (median 10 days vs 15 days, 
retrospectively, p<0.001) (Table 1)[12]. Another rand-
omized, open-label trial which included hospitalized 
Covid-19 patients with pneumonia showed no differ-
ence in efficacy between a 5 day and a 10-day treatment 
with remdesivir, although it was shown that a 10-day 
course may be of benefit for patients who progressed 
to mechanical ventilation[13]. In the large open-labelled 
randomized Solidarity trial 2743 patients were assigned 
to the remdesivir group and 2708 to the control arm. 
There was no difference in mortality between patients 
who received remdesivir versus controls (Rate ratio, 
0.95 (95% CI, 0.81–1.11))[14]. In a double-blind, rand-
omized, placebo-controlled trial remdesivir given with 
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eight patients (10%) in the treatment group[27]. In the 
study by Borba et al, QTc dynamics was evaluated and 
QTc increased to >500 milliseconds in 18.9% high-
dose recipients and 11.1% low-dose recipients. Two 
high-dose chloroquine recipients developed VT, but 
no Torsade de pointes was reported[28]. The trial which 
compared two doses of chloroquine (600 mg CQ twice 
daily for 10 days vs 450 mg twice daily on day 1 and 
once daily for 4 days) for COVID-19, was stopped ear-
ly because of a higher mortality rate in the high-dose 
group (39.0% versus 15.0% in the low-dosage group at 
day 13) after enrolment of 81 participants out of a pre-
defined sample size of 440[28].
 The most recent and high-quality evidence come 
from two randomized-controlled trials (RECOVERY 
and SOLIDARITY) that suggest little to no benefit of 
treatment of COVID-19 with hydroxychloroquine[14, 
29]. The Executive group of the WHO SOLIDARITY tri-
al enrolled 11,330 adults and reported death at 28-day 
in 104 of 947 patients receiving hydroxychloroquine 
and in 84 of 906 receiving standard-of-care (RR 1.19; 
95% CI, 0.89 to 1.59; P = 0.23)[14]. Similarly, in the RE-
COVERY trial the patient’s death by 28 days occurred 
in 27% patients in the hydroxychloroquine group and 
in 25% in the standard-of-care group (RR 1.09; 95% 
confidence interval [CI], 0.97 to 1.23; P=0.15), with 
consistent results in subgroups of patients. A small 
excess of cardiac deaths (0.4%) was noted but the in-
cidence of new major cardiac arrhythmia among the 
patients who received hydroxychloroquine was ab-
sent[29]. Some groups examined the use of the hydroxy-
chloroquine in mild-to-moderate COVID-19 patients. 
In one of those studies conducted in the United States 
and Canada, hydroxychloroquine (800 mg followed by 
600 mg in 6 to 8 hours, then 600 mg daily for 4 days) or 
placebo were administered to non-hospitalized adults. 
At 14 days, change in symptom severity was similar in 
both groups (difference: relative, 12%; absolute, −0.27 
point [95% CI, −0.61 to 0.07 point]; P = 0.117), while 
24% of participants receiving hydroxychloroquine had 
ongoing symptoms compared with 30% receiving pla-
cebo (P = 0.21). Medication adverse effects were re-
ported in 43% of participants receiving hydroxychlo-
roquine versus 22% in placebo group (P < 0.001)[30]. 
Another group conducted a multicentre, randomized 
controlled trial in mild-to-moderate hospitalized pa-
tients testing use of hydroxychloroquine alone (400 
mg twice daily for 7 days) and with azithromycin (400 
mg hydroxychloroquine twice daily plus 500 mg azith-
romycin once daily for 7 days). Compared with stand-
ard-of-care, hydroxychloroquine alone (OR, 1.21; 95% 
CI, 0.69 to 2.11; P=1.00) or hydroxychloroquine plus 
azithromycin (OR, 0.99; 95% CI, 0.57 to 1.73; P=1.00) 
NCT04336904, NCT04425460, NCT04600895). Most 
common adverse events reported in the WHO phar-
macovigilance database suspected to be caused by 
the favipravir included increased hepatic enzymes, 
nausea, vomiting, tachycardia, and diarrhoea. Severe 
adverse events included blood and lymphatic, cardi-
ac and hepatobiliary disorders, injury poisoning, and 
procedural complications[21]. Currently, there is not 
enough data to recommend its use for patients with 
renal impairment or patients on haemodialysis while 
in patients with hepatic impairment adjustment of 
dosage should be considered[22].
Chloroquine/hydroxychloroquine 
- Efficacy unproven, adverse events concern
 Soon after emergence of the new virus, in vit-
ro studies have reported in vitro inhibition of SARS-
CoV-2 virus by both chloroquine and hydroxychlo-
roquine, with hydroxychloroquine potentially having 
more potent antiviral activity[23]. Current literature data 
are controversial and contradictory, suggesting limited 
or no benefit of chloroquine and hydroxychloroquine 
for COVID-19 patients, with concerns about adverse 
events. At the time of writing this paper, The Nation-
al Institutes of Health recommends against the use of 
chloroquine or hydroxychloroquine, with or without 
azithromycin, for COVID-19 treatment[9]. Initial small 
clinical reports seemed promising, but most lacked 
proper methodology. For example, the French study in-
volving 36 adults with COVID-19 reported that the use 
of hydroxychloroquine (200 mg three times per day for 
10 days) was associated with a higher rate of undetecta-
ble SARS-CoV-2 RNA in nasopharyngeal specimens at 
day 6 compared with no specific treatment (70 vs 12.5 
%)[24]. However, it was a non-randomized, open-label, 
underpowered study with other methodological is-
sues. On the other hand, in an observational study of 
1446 patients hospitalized in New York, 811 patients 
were treated with hydroxychloroquine, which was as-
sociated with a higher risk of intubation or death (HR 
2.37). In the multivariable analysis, this association 
was not significant (HR [95% CI 0.82-1.32])[25]. This 
study had serious limitations as well, such are dispro-
portional differences between the patient groups and 
lack of randomization. In a retrospective cohort study 
on 7914 COVID-19 patients, treatment with hydrox-
ychloroquine, azithromycin, or both, compared with 
neither treatment, was not significantly associated with 
differences in in-hospital mortality[26]. Concerns about 
serious side effects have been raised as well, including 
cardiotoxicity. The observational study by Mahévas et 
al. from France reported electrocardiographic modifi-
cations that required discontinuation of treatment in 
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Lopinavir/ritonavir 
- Clinical benefit not demonstrated
 Lopinavir/ritonavir is a combined protease in-
hibitor and booster, primarily used for the treatment 
of HIV infection. Lopinavir showed antiviral effect 
against SARS-CoV and MERS-CoV and it was recently 
showed that it inhibits replication of SARS-CoV-2[38]. 
In the report of pharmacokinetic data of lopinavir and 
ritonavir in COVID-19 patients (400 mg of lopinavir 
and 100 mg of ritonavir twice daily for 3 to 10 days be-
fore analysis) it was shown that approximately 60- to 
120-fold higher concentrations are required to reach 
the assumed EC50[39]. In the early pandemic, reports of 
treatment with lopinavir/ritonavir were mostly small 
retrospective, non-randomized studies and case re-
ports, which made definitive conclusions about benefit 
for COVID-19 patients difficult[6]. In the RECOVERY 
study on hospitalized patients with COVID-19, lopina-
vir–ritonavir was not associated with reductions in 28-
day mortality, length of hospital stay, or risk of progres-
sion to invasive mechanical ventilation or death[40]. In 
a randomized control trial on 199 COVID-19 patients, 
lopinavir/ritonavir (400/100 mg twice daily for 14 
days) also showed no significant benefit than standard 
care in terms of the time to clinical improvement (HR 
1.31 [95%CI, 0.95 to 1.80]), mortality at 28 days (19.2% 
vs 25.0%, respectively; 95% CI, −17.3 to 5.7), and viral 
RNA was detectable in similar percentages of patients 
at various times[41]. However, this study was under-
powered and included mainly patients with severe in-
fection, and the median time from symptom onset to 
treatment was 13 days[42]. Lopinavir and ritonavir are 
inhibitors of the P450 cytochrome and they have signif-
icant drug-drug interactions and adverse drug events. 
Common reported adverse effects are gastrointestinal 
(diarrhoea, nausea), hepatotoxicity, blood glucose dis-
orders and rash[43]. In the study by Cao et al. lopinavir/
ritonavir was stopped early in 13.8% of patients due 
to adverse events, but percentages of patients who re-
ported adverse events were similar in lopinavir-ritona-
vir group and in the standard-care group (48.4% vs 
49.5%, respectively)[41]. National Institutes for Health 
and Infectious Diseases Society of America Guidelines 
recommend against using lopinavir/ritonavir to treat 
COVID-19, except in a clinical trial[9, 10]. In silico stud-
ies identified some other potential protease inhibitors 
for treatment of COVID-19 and trials of darunavir/
cobicistat for treatment of COVID-19 (NCT04252274) 
is ongoing in Shangai, China[44]. However, the manu-
facturer of darunavir (Johnson & Johnson) has warned 
that there is no clinical nor pharmacological evidence 
to support the inclusion of darunavir-based treatment 
in guidelines for COVID-19, nor are there published 
did not differ in clinical benefit at 15 days. Adverse 
events, namely prolongation of the QTc interval and 
elevation of liver-enzyme levels were more frequent in 
patients receiving hydroxychloroquine, alone or with 
azithromycin, than in controls[31]. Administration of 
hydroxychloroquine as post-exposure prophylaxis af-
ter high- or moderate-risk exposure to COVID-19 did 
not prevent illness as well[32].
Ribavirin - Clinical benefit not demonstrated
 Ribavirin is a guanosine analogue with a broad- 
spectrum antiviral activity. Interest in it grew after the 
emergence of SARS-CoV-2, however, relevant clinical 
data on its effectiveness and use in SARS-CoV-2 pa-
tients is limited. Most of the data comes from research 
on SARS-CoV-1; for example, a study of ribavirin given 
in combination with lopinavir/ritonavir for the treat-
ment of patients with acute respiratory distress syn-
drome (ARDS) vs lopinavir/ritonavir alone[33]. In vitro 
report of ribavirin effectiveness against SARS-CoV-2 
revealed that the required effective concentration is 
quite high (EC50 = 109.50 μM), rising concerns about 
side effects[8]. In the meantime, the first clinical trial 
on COVID-19 treatment with ribavirin in combina-
tion with interferon beta-1b and/or lopinavir–ritona-
vir has been published[34]. Patients were treated either 
with triple combination of interferon beta-1b, lopina-
vir–ritonavir, and ribavirin, or lopinavir–ritonavir and 
ribavirin, while the control group received lopinavir–
ritonavir. The results showed reduction in duration of 
RT-PCR positivity and viral load accompanied with 
clinical improvement and shorter duration of hospital 
stay. However, due to the combination treatment, it can-
not be determined which of the compounds contribut-
ed the most to the outcomes[34]. In a recently published 
retrospective cohort study ribavirin versus standard 
therapy was tested in severe COVID-19. The negative 
conversion time of RT-PCR in the ribavirin group was 
12.8 ± 4.1 days compared with 14.1 ± 3.5 days in the 
control group (P = 0.314). Of 115 patients in the riba-
virin group, 17.1% died compared with 24.6% in the 
control group (P = 0.475). Adverse effects were similar 
between the two groups[35]. In another small study of 62 
patients with severe COVID-19, the researchers test-
ed sofosbuvir/daclatasvir or ribavirin. All participants 
also received the recommended standard treatment (at 
that time lopinavir/ritonavir and hydroxychloroquine). 
The mortality in the sofosbuvir/daclatasvir group was 
6% vs 33% in the ribavirin group[36]. On the other hand, 
a small randomized trial testing efficacy of sofosbuvir 
plus daclatasvir in combination with ribavirin showed 
no difference in the number of deaths between the 
groups (0 versus 3, P = 0.234)[37].
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(treatment with remdesivir was also given) in a recent-
ly published randomized double-blind trial including 
hospitalized patients who had symptoms attributable 
to COVID-19 of 12 or less days. There was no effect of 
bamlanivimab on clinical improvement compared to 
placebo (OR 0.85, 95% CI 0.56 to 1.29). There was also 
no benefit it terms of outcome (a composite endpoint 
of death, serious laboratory or clinical adverse events), 
being 19% in the bamlanivimib group and 14% in the 
placebo group[52]. There is currently very little data on the 
clinical effectiveness of REGN-COV2 cocktail, results 
of randomized trials are expected in the near future.
Interleukin inhibitors – more data needed
 Severe organ damage, particularly lung damage, 
is probably caused by an excessive immune response 
and „cytokine storm”. This can result in increased al-
veolar-capillary gas exchange and lead to hypoxemia. 
Interleukins are mediators of this immune response 
and in a study from Wuhan, China interleukin-6 (IL-
6) was elevated in COVID-19 non survivors compared
with survivors[53].
 Clinical trials of several monoclonal antibodies 
against IL-6 are underway, some of which have already 
been published. Tocilizumab, a monoclonal antibody 
IL-6 receptor antagonist is approved for treating rheu-
matoid arthritis and cytokine release syndrome[6]. In a 
case series of 20 patients with severe or critical COV-
ID-19 treated with tocilizumab, 75% had better oxy-
genation within 5 days, in 90.5% CT scans improved 
and the defervescence achieved on the first day after 
the treatment[54]. Another retrospective study on 25 pa-
tients treated with tocilizumab and investigational an-
tiviral drugs showed a decline in inflammatory mark-
ers, reduced ventilatory support requirements and 
radiological improvement[55]. Initial nonrandomized 
studies were promising as well. One meta-analysis of 
nonrandomized studies reported that the tocilizumab 
group had lower mortality than the control group. The 
risk ratio was 0.27 (95% CI, 0.12–0.59) and the risk 
difference was 12% (95% CI, 4.6%–20%) for tocili-
zumab[56].
 Randomized clinical trials were not as promising. 
An open-label, randomized clinical trial of 131 non-
ICU patients with COVID-19 and pneumonia requir-
ing oxygen support compared treatment with tocili-
zumab versus standard care. Though tocilizumab did 
not reduce World Health Organization 10-point Clini-
cal Progression Scale (WHO-CPS) scores lower than 5 
at day 4, in the tocilizumab group 12% (95% CI −28% 
to 4%) fewer patients needed non-invasive ventilation 
(NIV), mechanical ventilation (MV), or died by day 
14. No difference on day 28 mortality was found[57].
data on the safety and efficacy profile of darunavir in 
treatment of COVID-19[45, 46].
Immune based therapy
Convalescent plasma- more data needed
 The Food and Drug Administration has approved 
the emergency use of convalescent plasma for the 
treatment of COVID-19[47]. Since then, many patients 
received convalescent plasma, particularly in the 
USA where it has been estimated that > 70 000 pa-
tients received convalescent plasma[9]. However, there 
is still little data from randomized trials published 
in peer-reviewed journals regarding the use of con-
valescent plasma. Four randomized trials have been 
peer-reviewed and published as of January 2021, of 
which only one showed clinical benefits[48] (Table 1). 
In this double-blind randomized study convalescent 
plasma was given to patients older than 75 years of 
age, regardless of concurrent comorbidity, or between 
65 and 74 years of age with at least one comorbidity. 
Convalescent plasma with high titres (IgG titre great-
er than 1:1000 against SARS-CoV-2 spike protein) 
was given within 72 hours after onset of symptoms. 
Of 80 patients who were given convalescent plasma 
13 (16%) progressed to severe disease whereas in the 
placebo group 25 (31%) of 80 progressed (relative risk 
reduction of 48%). Administration of convalescent 
plasma is not without adverse effects. In a published 
report of a convenience sample of 20000 patients, 13 
deaths and 83 nonfatal serious events (37 circulatory 
overload events, 20 lung injury events, and 26 severe 
allergic reactions) have been reported as possibly or 
probably related to convalescent plasma[49]. There were 
also thromboembolic or thrombotic events (n=87; 
<1%), and cardiac events (n=680, ~3%) reported.
Monoclonal antibodies - more data needed
 Antibodies with high and broad neutralizing ca-
pacity, particularly those that bind to the receptor 
binding domain of the spike protein block the entry 
of SARS-CoV-2 virus into target cells and as such are 
promising agents for both prophylaxis and treatment 
of COVID-19. The Food and Drug Administration 
has granted emergency approval for two formulations 
of monoclonal antibodies for the treatment of COV-
ID-19: bamlanivimab and the casirivimab/imdevimab 
(REGN-COV2) cocktail. Both monoclonal antibody 
formulations showed a reduction of SARS-CoV-2 viral 
load from the nasopharyngeal swabs in randomized 
double blind clinical trials[50, 51].
 LY-CoV555 (also known as bamlanivimab) did not 
show any efficacy compared to best standard of care 
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care group (22.9% vs. 25.7%, age-adjusted rate ratio, 
0.83; 95% CI, 0.75 to 0.93; P<0.001). In patients treated 
with dexamethasone the incidence of death was low-
er than in the usual care group in those on invasive 
mechanical ventilation (29.3% vs. 41.4%; rate ratio, 
0.64; 95% CI, 0.51 to 0.81) and among those receiv-
ing oxygen (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 
0.72 to 0.94). There was no statistically significant dif-
ference among patients who did not receive oxygen 
at randomization however, there was numerically a 
worse outcome in those who received dexamethasone 
(17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.91 to 1.55)
[63]. This study had also some limitations: lack of data 
on viral clearance and the level of oxygen support[64]. 
In a study of 149 critically ill patients with COVID-19 
and acute respiratory failure, low-dose hydrocortisone 
vs. placebo, did not significantly reduce treatment fail-
ure (defined as death or persistent respiratory support) 
at day 21 (difference of proportions, -8.6% [95.48% 
CI, -24.9% to 7.7%]; P = 0.29)[65]. In the CoDEX ran-
domized clinical trial of patients with moderate or 
severe ARDS due to COVID-19, use of intravenous 
dexamethasone (20 mg daily for 5 days, then 10 mg 
daily for 5 days or until ICU discharge) plus standard 
care compared with standard care alone resulted in a 
significant increase in the number of ventilator-free 
days over 28 days (difference, 2.26; 95% CI, 0.2-4.38; P 
= 0.04)[66]. In a randomized placebo-controlled study 
from Brazil 416 patients with suspected or confirmed 
COVID-19 pneumonia received a short course meth-
ylprednisolone (0.5 mg/kg twice daily for 5 days) or 
placebo. There was no difference between the groups 
in mortality at day 7, 14 and 28-day or in the need for 
mechanical ventilation. The 28-day mortality rate in 
patients >60 years old was lower in the methylpred-
nisolone group vs. placebo group (46.6% vs. 61.9% of 
participants, respectively; HR 0.63; 95% CI, 0.41–0.98; 
P = 0.039)[67]. In a retrospective study of 201 patients 
with COVID-19 from China, among patients with 
ARDS (26.4%), treatment with methylprednisolone 
decreased the risk of death (HR, 0.38 [95% CI 0.20-
0.72])[68]. In 11/31 COVID-19 patients in China who 
received corticosteroids the analysis showed no as-
sociation between corticosteroid treatment and virus 
clearance time (HR, 1.26 [95% CI 0.58-2.74]), hospital 
length of stay (HR 0.77 [95% CI, 0.33-1.78]), or du-
ration of symptoms (HR 0.86 [95% CI, 0.40-1.83])[69]. 
A meta-analysis that evaluated the efficacy of systemic 
corticosteroids (dexamethasone, hydrocortisone, and 
methylprednisolone) in 1703 critically ill patients with 
COVID-19 compared with usual care or placebo, treat-
ment with corticosteroids was associated with lower 
28-day all-cause mortality (summary OR, 0.66 [95% 
Another randomized, double-blind, placebo-con-
trolled trial involving patients with confirmed severe 
SARS-CoV-2 infection who received tocilizumab and 
controls, was inconclusive. The hazard ratio for intu-
bation or death in the tocilizumab group as compared 
with the placebo group was 0.83 (95% CI, 0.38 to 1.81; 
P=0.64), and the hazard ratio for disease worsening 
was 1.11 (95% CI, 0.59 to 2.10; P=0.73)[58]. Other ran-
domized clinical trial reported lack of benefit of tocili-
zumab treatment for COVID-19 as well[59]. Multiple 
RCTs are currently underway, comparing tocilizumab 
and corticosteroids (NCT04345445, NCT04377503), 
combining tocilizumab, hydroxychloroquine and 
azithromycin (NCT04332094) and tocilizumab with 
favipravir (NCT04310228).
 Sarilumab is an IL-6 antagonist being investi-
gated for treatment of COVID-19 in several stud-
ies (NCT04357808, NCT04357860, NCT04324073). 
However, in the Phase 3 analysis, sarilumab had no 
notable benefit on clinical outcomes in the severe and 
critical groups, versus placebo[60].
 Some groups tested if anakinra, a recombinant 
IL-1 receptor antagonist, might help to neutralize the 
hyperinflammatory state. Initial small cohort study 
in France with 52 consecutive patients included in 
the anakinra group and 44 historical patients as con-
trols was promising. Admission to the ICU for inva-
sive mechanical ventilation or death occurred in 13 
(25%) patients in the anakinra group and 32 (73%) 
patients in the historical group (HR 0.22 [95% CI 0.11 
to 0.41); p=0.0002)[61]. On the other hand, in a recent-
ly published cohort study of critically ill COVID-19 
patients, no significant differences in thrombocyte 
counts, PaO2/FiO2 ratio, or total SOFA score were ob-
served in the anakinra group[62]. Randomized control 
trials are underway (NCT04603742, NCT04643678, 
NCT04443881).
Corticosteroids - benefit demonstrated
 The benefit of corticosteroid use in septic shock is 
due to alleviating the host immune response and thus 
preventing the damage to organism. The idea for use of 
corticosteroids in COVID-19 patients was to decrease 
the host inflammatory responses in the lungs[6]. How-
ever, results from studies of corticosteroids in patients 
with SARS and MERS showed no improved survival 
and indicated an association with later viral clearance 
from the respiratory tract and blood and high rate of 
complications[6]. In the RECOVERY study 2104 COV-
ID-19 patients were assigned to receive dexametha-
sone (6 mg once daily oral or intravenous for 10 days) 
and 4321 received usual care. The 28-day mortality 
was lower in the dexamethasone group vs. the usual 
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es to enhance infection[72]. However, the clinical data 
on the use of ivermectin are limited. In a study from 
Egypt which included 400 patients with confirmed 
COVID-19 patients with mild/moderate and severe 
COVID-19 who were treated with ivermectin plus 
standard of care (azithromycin, vitamin C, zinc, lacto-
ferrin, acetylcysteine and prophylactic or therapeutic 
anticoagulation) had lower mortality rate (0% and 2%, 
respectively) in comparison to patients who received 
hydroxychloroquine and standard of care (4% and 
20%, respectively). Also, they had substantial improve-
ment in laboratory parameters one week after treat-
ment (p<0.001)[73]. A retrospective study of 280 pa-
tients hospitalized due to COVID-19 showed lower 
mortality in patients who were treated with ivermectin 
(15.0% vs. 25.2%; OR, 0.52; 95% CI, 0.29-0.96; P = 
0.03). However, patients in both groups (ivermectin 
and no-ivermectin) also received hydroxychloroquine, 
azithromycin, or both, and those who received iver-
mectin were also more likely to receive corticoster-
oids[74]. In a study of 180 mild to severe COVID-19 
patients from Iranian authors a shorter hospital stay 
was observed in ivermectin treated groups compared 
to two groups treated with common regimen (hydrox-
ychloroquine) (P=0.006 and P=0.025, respectively). 
The lowest mortality rate (0%) and hospital stay (me-
dian: 5 days) was recorded in patients treated with a 
single dose of ivermectin (400 mcg/kg)[75]. Several ran-
domized controlled clinical trials of ivermectin are un-
derway (NCT04429711, NCT04530474, NCT04529525, 
NCT04602507). Currently, the National Institutes of 
Health recommend against the use of ivermectin for 
COVID-19 except in the clinical trials[9].
Summary guidance
 The optimal treatment approach for COVID-19 
is still not defined. We still have little data from large 
RCT which would guide the treatment of COVID-19. 
Findings from major studies on pharmacologic treat-
ment of COVID-19 are summarized in Table 1 and 
recommendations are given in Table 2. The only large 
double-blind RCT reported so far showed only a mod-
est benefit of the use of remdesivir[12] and the large 
Solidarity trial showed no survival benefit[14]. Based on 
the available evidence it seems prudent to give remde-
sivir to patients who need low-flow oxygen support. 
Although subgroup analyses should be interpreted 
with caution, in the Solidarity trial those with respira-
tory support but not on mechanical ventilation had a 
somewhat lower risk for death (Rate Ratio 0.86, 95% 
CI 0.67 to 1.11)[14]. Also, a subgroup analysis of ACTT-
1 in patients receiving low-flow oxygen suggested a 
mortality benefit in those receiving remdesivir (Rate 
CI, 0.53-0.82], P < .001)[70]. The fixed-effect summary 
OR for the association with all-cause mortality for dex-
amethasone was 0.64 (95% CI, 0.50–0.82; P < 0.001) in 
three trials with 1282 patients[70]. RCTs investigating 
the potential of methylprednisolone (NCT04673162, 
NCT04343729, NCT04438980), dexamethasone 
(NCT04344730, NCT04640168) and hydrocortisone 
(NCT04348305, NCT04366115) are now in different 
phases. National Institutes for Health Guidelines and 
Infectious Diseases Society of America Guidelines do 
not recommend the use of dexamethasone in patients 
who do not require supplemental oxygen, but it is rec-
ommended in those who need supplemental oxygen 
through nasal cannula, masks, or high flow device, 
non-invasive or invasive mechanical ventilation or 
ECMO. Recommended dose is 6 mg PO or IV once 
daily for 10 days or until hospital discharge[9,10].
Baricitinib - more data needed
 Baricitinib is an oral Janus kinase (JAK) inhibitor 
approved by the FDA for the treatment of rheumatoid 
arthritis. The FDA issued an Emergency Use Authori-
zation in November 2020 for the use of baricitinib with 
remdesivir in hospitalized COVID-19 patients aged 
≥2 years who require supplemental oxygen, invasive 
mechanical ventilation, or ECMO[9]. A randomized 
placebo-controlled study of 1033 patients treated with 
baricitinib plus remdesivir or placebo plus remdesivir 
showed that patients treated with baricitinib plus rem-
desivir recovered faster (median, 7 days vs. 8 days; rate 
ratio for recovery, 1.16; 95%CI, 1.01 to 1.32; P=0.03). 
Time to recovery among patients on non-invasive ven-
tilation or high-flow oxygen was 10 days in baricitinib 
plus remdesivir vs. 18 days in the control group (rate 
ratio for recovery, 1.51; 95% CI, 1.10 to 2.08). The 28-
day mortality was 5.1% in the combination group and 
7.8% in the control group (hazard ratio for death, 0.65; 
95% CI, 0.39 to 1.09)[15]. In NIH treatment guidelines 
baricitinib in combination with remdesivir for the 
treatment of COVID-19 in hospitalized, non-intubat-
ed patients who require oxygen supplementation is 
recommended in the rare circumstances where corti-
costeroids cannot be used[9].
Ivermectin - more data needed
 Ivermectin is an antiparasitic drug approved for the 
treatment of onchocerciasis, helminthiases, and sca-
bies[9]. It was shown to be effective in vitro against the 
viruses Zika, dengue, HIV, and yellow fever[9]. It is ef-
fective SARS-CoV-2 inhibitor in vitro[71]. Yang et al. 
showed ability of ivermectin to target the host impor-
tin α/β1 nuclear transport proteins responsible for in-
tracellular transport process which is altered by virus-
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geting the receptor binding domain of the spike pro-
tein are emerging, those treatments should not be giv-
en routinely, and if given they should be administrated 
early, preferably within the first few days of sympto-
matic COVID-19[48-51].
 The only recommendation that can currently be 
given is the use of corticosteroids, of which the most 
robust data comes from the Recovery trial which used 
dexamethasone 6 mg per day for up to 10 days[63]. The 
greatest benefit was observed among patients receiv-
ing mechanical ventilation. Of note, there was no ben-
efit and even possible harm when dexamethasone was 
given to those who did not require oxygen supplemen-
tation at randomization.
Ratio 0.30, 95% CI 0.11 to 0.81)[14]. Currently, remde-
sivir has been recommended for the treatment of hos-
pitalized patients with severe COVID-19[9,10] (Table 
2). We should be reminded that fully powered blind-
ed RCTs are considered the gold standard for clinical 
trials that produce high quality evidence of treatment 
effect. Until such trials are reported we should aim not 
to harm our patients. Currently, because of safety con-
cerns and lack of proven benefit, chloroquine and hy-
droxychloroquine should not be used outside a closely 
monitored RCT. Other antiviral and immune-based 
therapy, including combination therapy should also be 
given through RCT. Although data on effectiveness of 
convalescent plasma and monoclonal antibodies tar-
Table 1. Overview of major randomized trials* on antiviral therapy for COVID-19 published till December 2020.
Tablica 1. Pregled značajnijih randomiziranih studija* o antivirusnom liječenju COVID-19 objavljenih do prosinca 2020.
Author/Study Number of patients 
studied/analyzed (N)
Type of study Conclusion Comment
Beigel JH et al. Remdesivir for the 
treatment of Covid-19 – final 









Remdesivir was superior to 
placebo in shortening the time 
to recovery in adults 
hospitalized with Covid-19 
and evidence of lower 
respiratory tract infection.
Mortality still high in the 
remdesivir group.
The primary outcome 
changed during the trial.
Goldman JD et al. Remdesivir for 5 
or 10 Days in Patients with Severe 
Covid-19. N Engl J Med, 2020; 
383:1827-1837. doi: 10.1056/
NEJMoa2015301. 
Remdesivir iv for 5 days 
(N=200)





No difference in efficacy 
between a 5 day and a 10 day 
course of remdesivir. 10 day 
course may be of benefit for 
patients who progressed to 
mechanical ventilation.
Lack of a randomized 
placebo control group. 
Only 44% of patients in the 
10-day arm completed the 
full treatment course.
Wang Y et al., Remdesivir in adults 
with severe COVID-19: a 
randomised, double-blind, 
placebo-controlled, multicentre 








Remdesivir use was not 
associated with a difference in 
time to clinical improvement 
and mortality at day 28, but 
patients with symptom 
duration of 10 days or less had 
faster time to clinical 
improvement.
Late initiation of treatment, 
more patients with 
hypertension, diabetes, or 
coronary artery disease in 
the remdesivir group.
Spinner CD, at al. Effect of 
Remdesivir vs Standard Care on 
Clinical Status at 11 Days in 
Patients With Moderate 
COVID-19: A Randomized 
Clinical Trial. JAMA, 2020 ; Sep 
15;324:1048-1057. doi: 10.1001/
jama.2020.16349.
Remdesivir iv 10-days 
(N = 197)
Remdesivir iv 5-days 
(N = 199)
Standard care (N = 200)
Randomized open 
label trial
At day 11 patients randomized 
to a 5-day course of 
remdesivir had a better 
clinical status compared with 
standard care, but patients 
randomized to a 10-day 
course did not.
The clinical significance of 
the findings are unclear.
Kalil AC. Baricitinib plus 
Remdesivir for Hospitalized Adults 
with Covid-19. N Engl J Med,  2020 
; doi: 10.1056/NEJMoa2031994. 
Remdesivir plus 
baricitinib (N=515)






Baricitinib plus remdesivir 
was superior to remdesivir 
alone in reducing recovery 
time and accelerating 
improvement in clinical status 
among patients with 
Covid-19, notably among 
those receiving high-flow 
oxygen or noninvasive 
ventilation.
No significant difference in 
mortality; the 28-day 
mortality was 5.1% in the 
combination group and 
7.8% in the control group. 
Baricitinib was given 
without corticosteroids.
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WHO Solidarity Trial Consortium. 
Repurposed Antiviral Drugs for 
Covid-19 —Interim WHO 
Solidarity Trial Results. N Engl J 









(including 651 to 
interferon plus lopinavir)





lopinavir, and interferon had 
little or no effect on overall 
mortality, initiation of 
ventilation, and duration of 
hospital stay.
No placebo group.
Horby P, et al.
Effect of hydroxychloroquine in 
hospitalized patients with 




Usual care (N= 3155)
Randomized open 
label trial
Those who received 
hydroxychloroquine did not 
have a lower incidence of 
death at 28 days than those 
who received usual care.
Patients receiving 
hydroxychloroquine while 
not on invasive mechanical 
ventilation at the time of 
randomization were more 
likely to subsequently 
require intubation or die 
during hospitalization than 
those who received the 
standard of care.
Cavalcanti AB et al. 
Hydroxychloroquine with or 
without Azithromycin in 
Mild-to-Moderate Covid-19. N 











Among patients hospitalized 
with mild- to-moderate 
Covid-19, the use of 
hydroxychloroquine, alone or 
with azithromycin, did not 
improve clinical status at 15 
days as compared with 
standard care.
More adverse events 




azithromycin than among 
those who received the 
standard of care.
Furtado RHM et al. Azithromycin 
in addition to standard of care 
versus standard of care alone in the 
treatment of patients admitted to 
the hospital with severe COVID-19 
in Brazil (COALITION II): a 






In patients with severe 
COVID-19, adding 
azithromycin to standard of 
care did not improve clinical 
outcomes.
All patient in the standard 
group received 
hydroxychloroquine.
RECOVERY Collaborative Group. 
Lopinavir-ritonavir in patients 
admitted to hospital with 
COVID-19 (RECOVERY): a 
randomised, controlled, open-label, 
platform trial. Lancet, 2020 ; 







Lopinavir-ritonavir was not 
associated with reductions in 
28-day mortality, duration of 
hospital stay, 




Cao B, et al. A trial of lopinavir-
ritonavir in adults hospitalized with 
severe Covid-19. N Engl J Med, 








No significant benefit of 
lopinavir-ritonavir in the time 
to clinical improvement, 
mortality at 28 day and viral 
clearance.
Trial was not blinded, there 
was a possibility of higher 
viral replication in the 
lopinavir-ritonavir group 
due to higher pharynx viral 
loads.
 Hung IF et al. Triple combination 
of interferon beta-1b, lopinavir–
ritonavir, and ribavirin in the 
treatment of patients admitted to 
hospital with COVID-19: an open- 
label, randomised, phase 2 trial. 














Early triple antiviral therapy 
was safe and superior to 
lopinavir–ritonavir alone in 
alleviating symptoms and 
shortening the duration of 
viral shedding and hospital 
stay in patients with mild to 
moderate COVID-19.
Need confirmation from 
larger phase 3 studies.
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Ahmed S.  A five-day course of 
ivermectin for the treatment of 
COVID-19 may reduce the duration 










Virological clearance was 
earlier in the 5-day ivermectin 
treatment arm versus the 
placebo group but not in the 
ivermectin + doxycycline arm. 
Libster R. et al. Early High-Titer 
Plasma Therapy to Prevent Severe 
Covid-19 in Older Adults. N Engl J 








trial of convalescent 
plasma with high 
IgG titers
Early administration of 
high-titer convalescent plasma 
against SARS-CoV-2 to mildly 
ill infected older adults 
reduced the progression of 
Covid-19.
Simonovich VA et al. A 
Randomized Trial of Convalescent 
Plasma in Covid-19 Severe 
Pneumonia. New Engl J Med, 2020 







No significant differences 
were observed in clinical 
status or overall mortality 
between groups.
Li L et al. Effect of Convalescent 
Plasma Therapy on Time to 
Clinical Improvement in Patients 
With Severe and Life-threatening 
COVID-19: A Randomized Clinical 
Trial. JAMA, 2020; 324:460-470. 
doi: 10.1001/jama.2020.10044.
Convalescent plasma in 
addition to standard 
treatment (N=52)
Standard treatment 




No improvement in clinical 
status during 28 days of 
follow-up among patients 
receiving convalescent plasma 
compared to standard care in 
patients with severe or 
life-threatening COVID-19.
The trial was terminated 
early because of the waning 
epidemic and difficulties in 
recruiting new patients.
Agarwal A et el. Convalescent 
plasma in the management of 
moderate covid-19 in adults in 
India: open label phase II 
multicentre randomised controlled 
trial (PLACID Trial). BMJ, 2020 ; 
371:m3939 http://dx.doi.
org/10.1136/bmj.m3939
Convalescent plasma in 
addition to best 
standard treatment 
(N=235)





Convalescent plasma was not 
associated with a reduction in 
progression to severe covid-19 
or all cause mortality.
Chen P et al. SARS-CoV-2 
Neutralizing Antibody LY-CoV555 
in Outpatients with Covid-19. N 
Engl J Med, 2020 ; doi: 10.1056/
NEJMoa2029849. Online ahead of 
print.
Outpatients with 
recently diagnosed mild 
or moderate Covid-19
A single intravenous 
infusion of neutralizing 
antibody LY-CoV555 in 
one of three doses (700 
mg, 2800 mg, or 7000 
mg), N=309
Placebo, N=143




Patients who received the 
2800-mg dose of LY-CoV555 
had a faster decline in viral 
load over time.
Results need confirmation 
from a larger trial. There 




LY-CoV555 is also known 
as bamlanivimab.
ACTIV-3/TICO LY-CoV555 Study 
Group. A Neutralizing Monoclonal 
Antibody for Hospitalized Patients 
with Covid-19. N Engl J Med, 2020 
; doi: 10.1056/NEJMoa2033130.
All patients received 







Among adult hospitalized 
patients who had a duration of 
symptoms of 12 days or less 
LY-CoV555, when 
coadministered with 
remdesivir, did not 
demonstrate efficacy




Weinreich DM. REGN-COV2, a 
Neutralizing Antibody Cocktail, in 
Outpatients with Covid-19. N Engl 









1–3 trial involving 
nonhospitalized 
patients 
The REGN-COV2 antibody 
cocktail reduced SARS-Cov-2 
viral load. Effect was greater 
in patients whose immune 
response had not yet been 
initiated or who had a high 
viral load at baseline.
An interim analysis mainly 
on virological data. Clinical 
data evolving.
REGN-COV2 is also 
known as casirivimab/
imdevimab.
*Peer reviewed randomized trials only.
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